Cargando…
Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study
BACKGROUND: Systemic therapy options for salivary cancers are limited. MyPathway (NCT02091141), a phase IIa study, evaluates targeted therapies in non-indicated tumor types with actionable molecular alterations. Here, we present the efficacy and safety results for a subgroup of MyPathway patients wi...
Autores principales: | Kurzrock, R., Bowles, D. W., Kang, H., Meric-Bernstam, F., Hainsworth, J., Spigel, D. R., Bose, R., Burris, H., Sweeney, C. J., Beattie, M. S., Blotner, S., Schulze, K., Cuchelkar, V., Swanton, C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743163/ https://www.ncbi.nlm.nih.gov/pubmed/32067683 http://dx.doi.org/10.1016/j.annonc.2019.11.018 |
Ejemplares similares
-
Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study
por: Friedman, Claire F., et al.
Publicado: (2022) -
Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm
por: Narita, Yusuke, et al.
Publicado: (2022) -
Signature program: a platform of basket trials
por: Slosberg, Eric D., et al.
Publicado: (2018) -
Basket Ball
Publicado: (1965) -
Basket Ball
Publicado: (1965)